FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Diabetic Foot Ulcer Trial to Initiate in 1H26 ...

I have a diabetic nonhealing ulcer on my right heel. I was told that the blood circulation in my foot is not very good, which ...

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; ...

Ulcers are open sores that develop on the lining of the body, often caused by damage to the tissue from inflammation or infection. They can occur in various parts, such as the mouth, stomach, small ...

Though it can cause extreme discoloration, there's a lot you can do treat it—and stop it from happening again.

Changes to a key component of the Patient Driven Payment Model remain in limbo two years after they were first proposed, but federal regulators are still poised to refine the system to accommodate for ...

Avoid unnecessary tests and antibiotics by applying evidence-based, cost-conscious infectious-disease decision-making, with ...

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; complet ...